Global represented Zhejiang Tianyuan, a major private human vaccines manufacturer providing a competitive product portfolio and pipeline in China, in selling its 85% stake, over RMB 850 million to Novartis; a worldwide leading multinational pharmaceutical company. As the first foreign investment in the domestic vaccine industry from a large M&A, this transaction was closed in March 2011, after the central and local governments’ careful review and examination.

A team of lawyers from Global Law Office, Shanghai, led by partners Alan Zhou and Zhang, Yu, assisted Tianyuan in its negotiation, deal structuring, and documentation, as well as securing government approval and ultimately closing the deal.